EU backs second biosimilar copy of Humira, world's top drug
June 23, 2017 at 07:55 AM EDT
FRANKFURT, June 23 (Reuters) - European regulators have recommended approval of a second copy of AbbVie's rheumatoid arthritis drug Humira, the world's top-selling medicine, in a further boost for so-called biosimilars in the region.
